Literature DB >> 29669722

Warming "Cold" Melanoma with TLR9 Agonists.

.   

Abstract

According to data from two ongoing phase I studies for patients with metastatic melanoma whose disease is refractory to PD-1 blockade, the addition of either CMP-001 or SD-101-both investigational TLR9 agonists-could help reverse this resistance. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29669722     DOI： 10.1158/2159-8290.CD-ND2018-004

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma?

Authors:  Abdullah Al Emran; Hsin-Yi Tseng; Mikaela C Coleman; Jessamy Tiffen; Stuart Cook; Helen M McGuire; Stuart Gallagher; Carl Feng; Peter Hersey
Journal:  Pigment Cell Melanoma Res       Date:  2020-02-20       Impact factor: 4.693

Review 2.  Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect.

Authors:  Nathan Suek; Luis Felipe Campesato; Taha Merghoub; Danny N Khalil
Journal:  Front Immunol       Date:  2019-04-02       Impact factor: 7.561

Review 3.  Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Authors:  Matilde Monti; Francesca Consoli; Raffaella Vescovi; Mattia Bugatti; William Vermi
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

Review 4.  Roles of Plasmacytoid Dendritic Cells in Gastric Cancer.

Authors:  Jinpu Yang; Xia Liu; Yiwen Cheng; Jingchen Zhang; Feng Ji; Zongxin Ling
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

5.  Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.

Authors:  Binghai Zhou; Jiuliang Yan; Lei Guo; Bo Zhang; Shuang Liu; Mincheng Yu; Zheng Chen; Kewei Zhang; Wentao Zhang; Xiaoqiang Li; Yongfeng Xu; Yongsheng Xiao; Jian Zhou; Jia Fan; Mien-Chie Hung; Hui Li; Qinghai Ye
Journal:  Theranostics       Date:  2020-05-17       Impact factor: 11.556

Review 6.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

7.  High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.

Authors:  Jingrong Qian; Hongxue Meng; Bowen Lv; Jie Wang; Yingying Lu; Liju Su; Shu Zhao; Wenhui Li
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 8.  Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.

Authors:  Youhai Jiang; Xiaofang Zhao; Jing Fu; Hongyang Wang
Journal:  Front Immunol       Date:  2020-03-12       Impact factor: 7.561

Review 9.  Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies.

Authors:  Miaoqin Chen; Shiman Hu; Yiling Li; Ting Ting Jiang; Hongchuan Jin; Lifeng Feng
Journal:  Signal Transduct Target Ther       Date:  2020-11-20

Review 10.  Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

Authors:  Nathan Karin
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.